Skip to main content
Fig. 2 | Journal of Nanobiotechnology

Fig. 2

From: Co-delivery of miR-29b and germacrone based on cyclic RGD-modified nanoparticles for liver fibrosis therapy

Fig. 2

Fluorescent images of activated HSCs incubated with ICG-NPs and ICG-RGD-NPs with or without free cRGD pretreatment for 4 h a; fluorescent images of activated HSCs incubated with ICG-RGD-NPs for 2 h, 4 h, 8 h and 12 h b; cell viability of blank NPs (1 mg/mL) and R-RGD-NPs (1 mg/mL) against HSCs and LO2 for 24 h, 48 h and 72 h c; cell viability of free GMO, G-RGD-NPs and G/R-RGD-NPs against HSCs d and LO2 cells e. Scale bar: 20 μm

Back to article page